{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:56:57Z","timestamp":1786636617406,"version":"build-2736575974"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Pharmacol"],"published-print":{"date-parts":[[2011]]},"DOI":"10.4103\/0253-7613.75659","type":"journal-article","created":{"date-parts":[[2011,1,24]],"date-time":"2011-01-24T08:22:24Z","timestamp":1295857344000},"page":"13","source":"Crossref","is-referenced-by-count":4,"title":["Clinical trials of antihypertensives: Nature of control and design"],"prefix":"10.4103","volume":"43","author":[{"given":"BhaswatS","family":"Chakraborty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0253-7613.75659-1","first-page":"217","volume-title":"Global burden of hypertension: Analysis of worldwide data","author":"Kearney","year":"2005","journal-title":"Lancet"},{"key":"key-10.4103\/0253-7613.75659-2","first-page":"11","volume-title":"Worldwide prevalence of hypertension: A systematic review","author":"Kearney","year":"2004","journal-title":"J Hypertens"},{"key":"key-10.4103\/0253-7613.75659-3","unstructured":"JNC-7. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure U.S. Department of Health And Human Services, NIH Publication No. 04-5230; 2004. p. 1-104."},{"key":"key-10.4103\/0253-7613.75659-4","unstructured":"Reference Card for JNC-7. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure U.S. Department of Health And Human Services, NIH Publication No. 04-5230; 2004. p. 1-2."},{"key":"key-10.4103\/0253-7613.75659-5","first-page":"294","volume-title":"Haemodynamic monitoring: Measurement of systemic blood pressure","author":"Scott","year":"1985","journal-title":"Can Anaesth Soc J"},{"key":"key-10.4103\/0253-7613.75659-6","doi-asserted-by":"crossref","unstructured":"Pater C. Beyond the Evidence of the New Hypertension Guidelines. Blood pressure measurement - Is it good enough for accurate diagnosis of hypertension? Time might be in, for a paradigm shift (I). Curr Control Trials Cardiovasc Med 2005;6:1-14","DOI":"10.1186\/1468-6708-6-6"},{"key":"key-10.4103\/0253-7613.75659-7","first-page":"CD002003","volume-title":"Beta-blockers for hypertension","author":"Wiysonge","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.4103\/0253-7613.75659-8","first-page":"257","volume-title":"Benefits and side effects of blood pressure lowering treatment: What was wrong with doxazosin in the ALLHAT?","author":"Gavras","year":"2001","journal-title":"Curr Control Trials Cardiovasc Med"},{"key":"key-10.4103\/0253-7613.75659-9","first-page":"771","volume-title":"Recent intervention studies with antihypertensive drugs and their influence on guidelines","author":"Rahn","year":"2003","journal-title":"Med Klin"},{"key":"key-10.4103\/0253-7613.75659-10","unstructured":"Centre for Drug Evaluation and Research, USA Food and Drug Administration. Guidance for industry - E12A: Principles for Clinical Evaluation of New Antihypertensive Drugs. 2002 Available form: http:\/\/www.fda.gov\/cder\/guidance\/index.htm [last accessed on 2000]"},{"key":"key-10.4103\/0253-7613.75659-11","first-page":"5","volume-title":"The ethics of using placebo in hypertension clinical trials","author":"Weber","year":"1999","journal-title":"J Hypertens"},{"key":"key-10.4103\/0253-7613.75659-12","first-page":"S66","volume-title":"Prevention of cardiovascular disease in hypertensive patients with normal renal function","author":"Wright","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"key-10.4103\/0253-7613.75659-13","first-page":"39","volume-title":"ALLHAT: Setting the record straight","author":"Davis","year":"2004","journal-title":"Ann Intern Med"},{"key":"key-10.4103\/0253-7613.75659-14","first-page":"393","volume-title":"Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","author":"Cushman","year":"2002","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"key-10.4103\/0253-7613.75659-15","unstructured":"Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA 2003;390:2859-61."},{"key":"key-10.4103\/0253-7613.75659-16","first-page":"995","volume-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"key-10.4103\/0253-7613.75659-17","first-page":"1491","volume-title":"Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: A Losartan Intervention for Endpoint Reduction sub-study.(LIFE-ISH)","author":"Kjeldsen","year":"2002","journal-title":"JAMA"},{"key":"key-10.4103\/0253-7613.75659-18","first-page":"861","volume-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.(RENAAL)","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0253-7613.75659-19","first-page":"895","volume-title":"Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial","author":"Dahlof","year":"2005","journal-title":"Lancet"},{"key":"key-10.4103\/0253-7613.75659-20","unstructured":"Pocock SJ. Clinical Trials - A Practical Approach. West Sussex, England: John Wiley and Sons; 2006."},{"key":"key-10.4103\/0253-7613.75659-21","unstructured":"Centre for Drug Evaluation and Research, USA Food and Drug Administration. Guidance for Clinical Trial Sponsors: Establishment and Operations of Clinical Trials Data Monitoring Committees. 2006 Available form: http:\/\/www.fda.gov\/cber\/gdlns\/clintrialdmc.htm [last accessed on 2006]"},{"key":"key-10.4103\/0253-7613.75659-22","first-page":"16","volume-title":"Long-term safety of antihypertensive therapy","author":"Grossman","year":"2006","journal-title":"Prog Cardiovasc Dis"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:58:59Z","timestamp":1786633139000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0253-7613.75659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011]]}},"alternative-id":["75659"],"URL":"https:\/\/doi.org\/10.4103\/0253-7613.75659","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2011]]}}}